Five things for pharma marketers to know: Friday, March 16, 2018

Share this content:

Pfizer's board has persuaded CEO Ian Read to stay on for another year after bumping his pay to $29 million and adding an $8 million bonus. The company was worried Reed would retire or move to another company. (Endpoints News)

The House of Representatives will look at the “right to try” bill again. The Republican-backed bill fell short of the two-thirds majority needed on Tuesday, but lawmakers plan to bring it to a vote again next week. The bill would make it easier for patients to try unapproved treatments when all others have failed. (Associated Press)

Lundbeck plans to buy Swiss pharma company Prexton Therapeutics in a deal worth as much as $1.1 billion. Prexton specializes in brain disorder treatments and has a drug for the treatment of Parkinson's disease in phase II testing. (Reuters)

Johnson & Johnson has received a $2.1 billion offer for diabetes business LifeScan. Private equity firm Platinum Equity made the offer, which J&J would need to accept by June. LifeScan generated about $1.5 billion in revenue last year. (CNBC)

Lawmakers have begun a push to require hospitals to report where drug discounts go. Senators want to see how much of the discounts are passed on to patients or where they otherwise go. (Modern Healthcare)


Share this content:
Scroll down to see the next article